Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069821 | 0.87 | CTSK (0.40) | CTSKBTKHSD11B1CYP2C9NFKB1 | |
| SCHEMBL20069820 | 0.81 | CTSK (0.42) | CTSKBTKHSD11B1CYP2C9NFKB1 | |
| SCHEMBL25694410 | 0.81 | CTSK (0.42) | CTSKBTKHSD11B1CYP2C9NFKB1 | |
| SCHEMBL14657161 | 0.81 | BTK (0.49) | CTSKBTKHSD11B1CYP2C9NFKB1 | |
| SCHEMBL24091122 | 0.80 | CTSK (0.41) | CTSKBTKHSD11B1CYP2C9NFKB1 | |
| SCHEMBL20147716 | 0.78 | CTSK (0.40) | CTSKBTKHSD11B1CYP2C9NFKB1 | |
| SCHEMBL31644391 | 0.78 | CTSK (0.40) | CTSKBTKHSD11B1CYP2C9NFKB1 | |
| SCHEMBL20413606 | 0.78 | CTSK (0.40) | CTSKBTKHSD11B1CYP2C9NFKB1 | |
| SCHEMBL27172452 | 0.77 | HSD11B1 (0.41) | CTSKBTKHSD11B1CYP2C9NFKB1 | |
| SCHEMBL20325892 | 0.73 | BTK (0.43) | CTSKBTKHSD11B1CYP2C9NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | CTSK 3569/4885BTK 444/4885HSD11B1 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.